142 related articles for article (PubMed ID: 29477796)
1. The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation.
Meregaglia M; Cairns J; Licitra L; Bossi P
Eur J Cancer; 2018 Apr; 93():89-98. PubMed ID: 29477796
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer.
Smith AF; Hall PS; Hulme CT; Dunn JA; McConkey CC; Rahman JK; McCabe C; Mehanna H
Eur J Cancer; 2017 Nov; 85():6-14. PubMed ID: 28881249
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer.
Acevedo JR; Fero KE; Wilson B; Sacco AG; Mell LK; Coffey CS; Murphy JD
J Clin Oncol; 2016 Nov; 34(32):3886-3891. PubMed ID: 27551113
[TBL] [Abstract][Full Text] [Related]
4. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.
van der Linden N; van Gils CW; Pescott CP; Buter J; Vergeer MR; Groot CA
Eur Arch Otorhinolaryngol; 2015 Aug; 272(8):2007-16. PubMed ID: 24943191
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.
Chan AL; Leung HW; Huang SF
Clin Drug Investig; 2011 Oct; 31(10):717-26. PubMed ID: 21744880
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer.
Sher DJ; Tishler RB; Annino D; Punglia RS
Ann Oncol; 2010 May; 21(5):1072-7. PubMed ID: 19833820
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
[TBL] [Abstract][Full Text] [Related]
8. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.
Retèl VP; van der Molen L; Hilgers FJ; Rasch CR; L'Ortye AA; Steuten LM; van Harten WH
BMC Cancer; 2011 Nov; 11():475. PubMed ID: 22051143
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
[TBL] [Abstract][Full Text] [Related]
11. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
Huntington SF; Svoboda J; Doshi JA
J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
[TBL] [Abstract][Full Text] [Related]
14. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of positron emission tomography-CT in the evaluation of cancer of unknown primary of the head and neck.
Smith KA; Dort JC; Hall SF; Rudmik L
Head Neck; 2015 Dec; 37(12):1781-7. PubMed ID: 24989937
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy.
Zhou GQ; Wu CF; Zhang J; Mao YP; Tang LL; Chen L; Guo R; Ma J; Sun Y
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1382-1391. PubMed ID: 29804816
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
